UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Imaging Outcomes in Clinical Trials of Treatments for Glaucoma

Lazaridis, G; Mohamed-Noriega, J; Aguilar-Munoa, S; Suzuki, K; Nomoto, H; Garway-Heath, DF; United Kingdom Glaucoma Treatment Study Investigators, .; (2021) Imaging Outcomes in Clinical Trials of Treatments for Glaucoma. Ophthalmology , 128 (8) pp. 1240-1242. 10.1016/j.ophtha.2020.11.027. Green open access

[thumbnail of Manuscript]
Preview
Text (Manuscript)
Lazaridis_Manuscript_File.pdf - Accepted Version

Download (135kB) | Preview
[thumbnail of Figures]
Preview
Text (Figures)
Lazaridis_Report_figures.pdf - Published Version

Download (202kB) | Preview

Abstract

Currently, all therapies for glaucoma have been licensed based on their ability to lower intraocular pressure (IOP). However, the main outcome of interest to people with glaucoma is vision-related (VR) quality of life (QoL). Instruments measuring VR QoL are unlikely to be sensitive enough to function as the primary outcome for clinical trials, 1 but they remain important as secondary outcomes to capture side-effects of treatment. Although lowering IOP has been shown to slow visual field (VF) loss, 2 IOP is a far-removed surrogate for VR QoL in glaucoma. Furthermore, IOP obviously would be an inappropriate outcome for a trial of a neuroprotective treatment with no effect on IOP. In contrast, the association of VR QoL measures with VF loss and other measures of vision has been established. 3 Measurements of visual function are recognized by regulatory authorities as the appropriate primary outcome measure for clinical trials in glaucoma, 4 and the major clinical trials that have evaluated vision function as the primary outcome have used progressive VF loss as the main outcome measure.

Type: Article
Title: Imaging Outcomes in Clinical Trials of Treatments for Glaucoma
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.ophtha.2020.11.027
Publisher version: https://dx.doi.org/10.1016/j.ophtha.2020.11.027
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Clinical trial, Glaucoma, Latanoprost, OCT, Optical coherence tomography, Visual fields, Visual function
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Institute of Ophthalmology
UCL > Provost and Vice Provost Offices > UCL BEAMS
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science > Dept of Electronic and Electrical Eng
URI: https://discovery.ucl.ac.uk/id/eprint/10124440
Downloads since deposit
66Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item